|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:available_on
|
generic drug
|
|
gptkbp:brand
|
gptkb:Januvia
|
|
gptkbp:can_be_combined_with
|
gptkb:metformin
sulfonylureas
thiazolidinediones
|
|
gptkbp:casnumber
|
489461-61-6
|
|
gptkbp:category
|
Category B
|
|
gptkbp:chemical_formula
|
C16 H15 F6 N5 O
|
|
gptkbp:class
|
antidiabetic agent
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:clinical_use
|
monotherapy or combination therapy
|
|
gptkbp:contraindication
|
hypersensitivity to sitagliptin
|
|
gptkbp:developed_by
|
gptkb:Merck_&_Co.
|
|
gptkbp:dosage_form
|
gptkb:tablet
100 mg once daily
|
|
gptkbp:effect_on_blood_sugar
|
lowers blood sugar levels
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
film-coated tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Sitagliptin
|
|
gptkbp:interacts_with
|
other antidiabetic medications
|
|
gptkbp:invention
|
gptkb:2023
|
|
gptkbp:lifespan
|
12.4 hours
|
|
gptkbp:marketed_as
|
gptkb:2006
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:mechanism_of_action
|
DPP-4 inhibitor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:patient_population
|
adults with type 2 diabetes
|
|
gptkbp:provides_guidance_on
|
gptkb:diabetes
gptkb:European_Association_for_the_Study_of_Diabetes
|
|
gptkbp:research
|
gptkb:SAVOR-TIMI_53
CARMELINA
CAROLINA
EXAMINE
TECOS
|
|
gptkbp:research_focus
|
long-term safety
renal outcomes
cardiovascular outcomes
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:safety_measures
|
post-marketing surveillance
|
|
gptkbp:side_effect
|
headache
nausea
allergic reactions
diarrhea
hypoglycemia
pancreatitis
nasopharyngitis
upper respiratory tract infection
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:target_enzyme
|
Dipeptidyl peptidase-4 (DPP-4)
|
|
gptkbp:used_for
|
type 2 diabetes
|
|
gptkbp:bfsParent
|
gptkb:Dapagliflozin/_Metformin/_Sitagliptin
|
|
gptkbp:bfsLayer
|
6
|